戻る Agenda
[V7-S2] Use and Application of Real World Data/Evidence Based on Next Generation Medical Infrastructure Act
Session Chair(s)
Shunichi Takahashi, PHD
Director, Head of Open Innovation Center Japan, Bayer Yakuhin, Ltd., Japan
Next Generation Medical Infrastructure Act become effective on 11th May 2018 and we are able to use medical related big data under proper information management. In this session, presenters will share overview of real world data which is being established under all Japan system and important topics of Next Generation Medical Infrastructure Act. In addition, as cases from pharmaceutical company, some presenters will share practices; 1) digital health tool development, 2) data application using EHR (electric health record) or PHR (personal health record). This session will have a time to discuss how should we grow digital health area under all Japan system.
Speaker(s)
Hiroshi Mizushima, PHD
Chief Senior Researcher, Center for Public Health Informatics, National Institute of Public Health, Japan
Use and Application of Real World Data
Haruka Nakada, JD, PHD
Division of Bioethics and Healthcare Law, Center for Public Health Sciences, National Cancer Center , Japan
Overview of Next Generation Medical Infrastructure Act
Masayuki Katsumata
Head, Value Evidence & Outcomes, GlaxoSmithKline K.K., Japan
Our Challenge for Innovation: Real World Data
Jovelle Fernandez, MD, PHD
Vice President, Japan Medical Officer and Head, Japan Medical Affairs, Takeda Pharmaceutical Company Limited, Japan
Value of Real World Evidence to Clinicians
Masakatsu Imoto
, Pharmaceuticals and Medical Devices Agency (PMDA), Japan